Stoke Therapeutics Inc (STOK): Market Capitalization-to-Revenue Ratio

Symbol and logo of brand Stoke Corp (STOK)

Stoke Therapeutics (STOK) is implementing RNA therapy to correct protein deficiency in the treatment of vision pathologies and epilepsy. The business relies on a narrow circle of oligonucleotide suppliers, minimizing risks through strategic alliances. High scientific potential and investments in TANGO technology are confirmed by the company's revenue valuation, where the metric settled at 60.40, reflecting market sentiment.

Price-to-Revenue Ratio: Stoke Corp (STOK) for 07/04/2022 - 11/13/2026

Stoke (STOK) - metric breakdowns and financial figures

- current quotes and average value forecast:
Market Price stoketherapeutics.com|STOK - Price Target Chart
- stock exchange capitalization data:
Market Value Stoke|STOK - Enterprise Value
- book capitalization indicators:
Book Value per Share Stoke Therapeutics|STOK - Company Book Value|Market Capitalization to Net Assets stoketherapeutics.com|STOK - Company Total Assets
- debt obligations and liquidity statistics:
Debt to Capital Stoke Therapeutics|STOK - Long-Term Debt to Equity Ratio|Short-Term Debt to Capital Stoke Corp|STOK - Company Total Debt|Debt to Book Capital Stoke|STOK - Company Long-Term Debts|Short-Term Debt Volume Stoke Therapeutics|Quick Liquidity Indicator stoketherapeutics.com
- company profitability and valuation multiples indicators:
STOK - Company Net Income|Company Profit Forecast Stoke Therapeutics|STOK - Price to Earnings Ratio|Market Cap to Projected Earnings Stoke Therapeutics Inc|STOK - Price/Earnings to Growth Multiple|Enterprise Value to Operating Income Before Depreciation Ratio Stoke|STOK - Profit before payment of interest, taxes and amortization|Net earnings per one share for the last twelve months Stoke Therapeutics|STOK - Earnings per share for the last twelve months|Quarterly EPS earnings growth stoketherapeutics.com|STOK - Earnings growth in current year|Projected earnings per share growth rate for next year Stoke Therapeutics
- total revenue and sales volume data:
STOK - Company Revenue|Company Revenue Forecast stoketherapeutics.com|STOK - P/S Multiple|Forward P/S Multiple Stoke
Summary company analytics:stoketherapeutics.com
Mass-produced product of Stoke

Professional selection of sustainable assets requires aligning market capitalization with actual cash flows from sales. By analyzing the P/S multiple, an investor evaluates the value of each unit of revenue for Stoke Therapeutics (STOK), which, combined with the team's authority in RNA therapies and successful R&D results, confirms the validity of current market expectations and the fundamental reliability of the business.

Competing companies

TEM - Price to Sales|Price-to-Revenue Ratio Qiagen QGEN|Market Capitalization-to-Revenue Ratio IONS|Repligen Corp. - P/S Multiple|RNA - P/S Multiple|CRISPR Therapeutics AG (CRSP) - Price-to-Revenue Ratio|Price-to-Sales Ratio WGS (genedx.com)|RARE (Ultragenyx) - P/S Multiple|Price to Sales Beam Therapeutics Inc BEAM|Market Cap to Revenue SRPT (Sarepta Therapeutics Inc)|P/S Multiple Twist Bioscience Corp (TWST)|10x Genomics, Inc. - Market Cap to Revenue|Market Cap to Sales Volume NTLA (intelliatx.com)|BioLife Solutions - P/S Multiple|Price-to-Revenue Coefficient Wave Life Sciences Ltd WVE|MAZE: P/S Multiple|Market Cap to Revenue Sionna Corp|Price-to-Revenue Ratio Prime Medicine, Inc.|tayshagtx.com (TSHA) - Price-to-Revenue Coefficient|Price-to-Revenue Ratio uniQure (QURE)|Price-to-Revenue Coefficient MeiraGTx Holdings|Regenxbio - Market Cap to Revenue|Market Cap to Sales Volume SLDB (Solid Corp)|OCGN - Price-to-Revenue Ratio|Price to Sales pacb.com|Benitec Biopharma (BNTC) - Price-to-Revenue Ratio|Design Therapeutics Inc (DSGN) - P/S Multiple|RCKT (Rocket Pharmaceuticals Inc) - P/S Multiple|Market Cap to Revenue Ratio FDMT (4D Molecular Corp)|Price-to-Revenue Ratio Lexeo Therapeutics (LXEO)|korrobio.com - Market Cap to Revenue Ratio|P/S Multiple EDIT (Editas Medicine)|P/S Multiple Silence Therapeutics PLC SLN|PRQR - Price-to-Revenue Ratio|Price-to-Revenue Coefficient Codexis, Inc. CDXS|SGMO (Sangamo Therapeutics) - Market Cap to Revenue|NAUT: Market Cap to Sales Volume|Price-to-Revenue Ratio Metagenomi|Price to Sales precisionbiosciences.com DTIL|Price-to-Revenue Ratio Generation Bio Co. (GBIO)|P/S Multiple Boundless Bio Inc (BOLD)|P/S Multiple XCUR (Exicure)|Imunon Inc (IMNN) - Price to Sales|PHIO: Market Cap to Revenue|Market Capitalization-to-Revenue Ratio MBIO (Mustang Bio, Inc.)|RNAZ (transcodetherapeutics.com) - Market Cap to Revenue|BNGO: Market Cap to Sales Volume|APDN (Applied DNA Sciences) - P/S Multiple|BLUE: Market Capitalization-to-Revenue Ratio|P/S Multiple IPA|OMGA - Price to Sales|Price-to-Revenue Ratio Singular Genomics Systems Inc OMIC|Market Capitalization-to-Revenue Ratio RGLS|Syros Pharmaceuticals - P/S Multiple|TBIO - P/S Multiple|TRACON Pharmaceuticals, Inc. (TCON) - Price-to-Revenue Ratio|Price-to-Sales Ratio UBX (Unity Biotechnology Inc.)